Management of Patients With Recovered Systolic Function

Progress in Cardiovascular Diseases

Volumn 58, Issue 4, 2016, Pages 434-443

  Basuray, Anupam ^a   Fang, James C ^b  

^a RIVERSIDE METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Heart failure recovered ejection fraction; Myocardial recovery; Reverse remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ALCOHOLIC CARDIOMYOPATHY; CHEMOTHERAPY INDUCED CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IRON OVERLOAD CARDIOMYOPATHY; ISCHEMIC CARDIOMYOPATHY; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL HISTORY; MYOCARDITIS; OUTCOME ASSESSMENT; PERIPARTUM CARDIOMYOPATHY; PROGNOSIS; REMISSION; REVIEW; SYSTOLIC DYSFUNCTION; TACHYCARDIA INDUCED CARDIOMYOPATHY; TAKOTSUBO CARDIOMYOPATHY; ADVERSE EFFECTS; CONVALESCENCE; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SYSTOLE;

ADRENERGIC BETA-ANTAGONISTS; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; PROGNOSIS; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SYSTOLE; VENTRICULAR REMODELING;

EID: 84959558393     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2016.01.003     Document Type: Review

References (92)

1. Yancy C.W., Jessup M., Bozkurt B. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 128:e240-e327.
2. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling 2000, 569-582.
3. Mann D.L., Barger P.M., Burkhoff D. Myocardial recovery and the failing heart. JACC 2012, 60:2465-2472.
4. Merlo M., Stolfo D., Anzini M., et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist?. J Am Heart Assoc 2015, 4:e001504. 10.1161/JAHA.114.001504.
5. Punnoose L.R., Givertz M.M., Lewis E.F., Pratibhu P., Stevenson L.W., Desai A.S. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail 2011, 17:527-532.
6. Basuray A., French B., Ky B., et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 2014, 129:2380-2387.
7. de Groote P., Fertin M., Duva Pentiah A., Goéminne C., Lamblin N., Bauters C. Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after β-blocker therapy. Circ Heart Fail 2014, 7:434-439.
8. Teeter W.A., Thibodeau J.T., Rao K., et al. The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: Implications for timing of implantable cardioverter-defibrillator implantation. Am Heart J 2012, 164:358-364.
9. Kramer D.G., Trikalinos T.A., Kent D.M., Antonopoulos G.V., Konstam M.A., Udelson J.E. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. JAC 2010, 56:392-406.
10. Dunlay S.M., Roger V.L., Weston S.A., Jiang R., Redfield M.M. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 2012, 5:720-726.
11. Hsu J.C., Solomon S.D., Bourgoun M., et al. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome. JAC 2012, 59:2366-2373.
12. Gasparini M., Regoli F., Ceriotti C., et al. Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy: temporal pattern and clinical predictors. Am Heart J 2008, 155:507-514.
13. Antonio N., Teixeira R., Coelho L., et al. Identification of "super-responders" to cardiac resynchronization therapy: the importance of symptom duration and left ventricular geometry. Europace 2009, 11:343-349.
14. Semigran M.J., Thaik C.M., Fifer M.A., Boucher C.A., Palacios I.F., Dec G.W. Exercise capacity and systolic and diastolic ventricular function after recovery from acute dilated cardiomyopathy. JAC 1994, 24:462-470.
15. Lampert M.B., Weinert L., Hibbard J., Korcarz C., Lindheimer M., Lang R.M. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 1997, 176:189-195.
16. Zecchin M., Proclemer A., Magnani S., et al. Long-term outcome of "super-responder" patients to cardiac resynchronization therapy. Europace 2014, 16:363-371.
17. Stevenson L.W. Heart failure with better ejection fraction: a modern diagnosis. Circulation 2014, 129:2364-2367.
18. Wilcox J.E., Fonarow G.C., Yancy C.W., et al. Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J 2012, 163:49-56.e2.
19. Cioffi G., Stefenelli C., Tarantini L., Opasich C. Prevalence, predictors, and prognostic implications of improvement in left ventricular systolic function and clinical status in patients >70 years of age with recently diagnosed systolic heart failure. Am J Cardiol 2003, 92:166-172.
20. Maybaum S., Mancini D., Xydas S., et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007, 115:2497-2505.
21. Dandel M., Weng Y., Siniawski H., et al. Heart failure reversal by ventricular unloading in patients with chronic cardiomyopathy: criteria for weaning from ventricular assist devices. Eur Heart J 2011, 32:1148-1160.
22. Dandel M., Weng Y., Siniawski H., et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation 2008, 118:S94-S105.
23. Birks E.J., George R.S., Hedger M., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011, 123:381-390.
24. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006, 355:1873-1884.
25. Simon M.A., Primack B.A., Teuteberg J., et al. Left ventricular remodeling and myocardial recovery on mechanical circulatory support. J Card Fail 2010, 16:99-105.
26. Mancini D.M., Beniaminovitz A., Levin H., et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998, 98:2383-2389.
27. Alderman E.L., Fisher L.D., Litwin P., et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983, 68:785-795.
28. Elefteriades J.A., Tolis G., Levi E., Mills L.K., Zaret B.L. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. JAC 1993, 22:1411-1417.
29. Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. JAC 2002, 39:1151-1158.
30. Giannuzzi P., Temporelli P.L., Bosimini E., et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. Am Heart J 2001, 141:131-138.
31. Funaro S., La Torre G., Madonna M., et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J 2009, 30:566-575.
32. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992, 327:685-691.
33. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
34. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
35. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056-1064.
36. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
37. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
38. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
39. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194-2199.
40. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
41. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
42. Pflugfelder P.W., Baird M.G., Tonkon M.J., DiBianco R., Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. JAC 1993, 22:1557-1563.
43. Nicholls M.G., Ikram H., Espiner E.A., Maslowski A.H., Scandrett M.S., Penman T. Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol 1982, 49:1497-1501.
44. Packer M., Gheorghiade M., Young J.B., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993, 329:1-7.
45. Velazquez E.J., Lee K.L., Deja M.A., et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011, 364:1607-1616.
46. Dec G.W., Palacios I.F., Fallon J.T., et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985, 312:885-890.
47. Steimle A.E., Stevenson L.W., Fonarow G.C., Hamilton M.A., Moriguchi J.D. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. JAC 1994, 23:553-559.
48. Boehmer J.P., Starling R.C., Cooper L.T., et al. Left ventricular assist device support and myocardial recovery in recent onset cardiomyopathy. J Card Fail 2012, 18:755-761. IMAC Investigators.
49. Lieberman E.B., Hutchins G.M., Herskowitz A., Rose N.R., Baughman K.L. Clinicopathologic description of myocarditis. JAC 1991, 18:1617-1626.
50. Waagstein F., Caidahl K., Wallentin I., Bergh C.H., Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989, 80:551-563.
51. Moon J., Ko Y.-G., Chung N., et al. Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 2009, 25:e147-e150.
52. Drakos S.G., Kfoury A.G., Stehlik J., et al. Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation 2012, 126:230-241.
53. McCarthy R.E., Boehmer J.P., Hruban R.H., et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000, 342:690-695.
54. Demakis J.G., Rahimtoola S.H., Sutton G.C., et al. Natural course of peripartum cardiomyopathy. Circulation 1971, 44:1053-1061.
55. O'Connell J.B., Costanzo-Nordin M.R., Subramanian R., et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. JAC 1986, 8:52-56.
56. Elkayam U., Tummala P.P., Rao K., et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001, 344:1567-1571.
57. Amos A.M., Jaber W.A., Russell S.D. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006, 152:509-513.
58. Loyaga-Rendon R.Y., Pamboukian S.V., Tallaj J.A., et al. Outcomes of patients with peripartum cardiomyopathy who received mechanical circulatory support: data from the interagency registry for mechanically assisted circulatory support. Circ Heart Fail 2014, 7:300-309.
59. McLaran C.J., Gersh B.J., Sugrue D.D., Hammill S.C., Seward J.B., Holmes D.R. Tachycardia induced myocardial dysfunction. A reversible phenomenon?. Br Heart J 1985, 53:323-327.
60. Singh B., Kaul U., Talwar K.K., Wasir H.S. Reversibility of "tachycardia induced cardiomyopathy" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol 1996, 19:1391-1392.
61. Chiladakis J.A., Vassilikos V.P., Maounis T.N., Cokkinos D.V., Manolis A.S. Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture. Pacing Clin Electrophysiol 1997, 20:953-959.
62. Cruz F.E., Cheriex E.C., Smeets J.L., et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. JAC 1990, 16:739-744.
63. Grimm W., Menz V., Hoffmann J., Maisch B. Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol 2001, 24:166-171.
64. Packer D.L., Bardy G.H., Worley S.J., et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986, 57:563-570.
65. Gillette P.C., Smith R.T., Garson A., et al. Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy. JAMA 1985, 253:391-392.
66. Olson T.M., Michels V.V., Ballew J.D., et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005, 293:447-454.
67. Stulak J.M., Dearani J.A., Daly R.C., Zehr K.J., Sundt T.M., Schaff H.V. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-Maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 2006, 82:494-501.
68. Nerheim P. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004, 110:247-252.
69. Ling L.H., Kalman J.M., Ellims A.H., et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol 2013, 6:697-704.
70. Prazak P., Pfisterer M., Osswald S., Buser P., Burkart F. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy. Eur Heart J 1996, 17:251-257.
71. Gavazzi A., De Maria R., Parolini M., Porcu M. Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol 2000, 85:1114-1118.
72. Fauchier L., Babuty D., Poret P., et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 2000, 21:306-314.
73. Teragaki M., Takeuchi K., Takeda T. Clinical and histologic features of alcohol drinkers with congestive heart failure. Am Heart J 1993, 125:808-817.
74. La Vecchia L.L., Bedogni F., Bozzola L., Bevilacqua P., Ometto R., Vincenzi M. Prediction of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters. Clin Cardiol 1996, 19:45-50.
75. Nicolás J.M., Fernández-Solà J., Estruch R., et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med 2002, 136:192-200.
76. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978, 62:865-872.
77. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. JACC 2010, 55:213-220.
78. Lipshultz S.E., Alvarez J.A., Scully R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2007, 94:525-533.
79. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
80. Ewer M.S. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
81. Ewer M.S., Type I.I. Chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23:2900-2902.
82. Tsuchihashi K., Ueshima K., Uchida T., et al. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. JAC 2001, 38:11-18.
83. Kurisu S., Sato H., Kawagoe T., et al. Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. Am Heart J 2002, 143:448-455.
84. Wittstein I.S., Thiemann D.R., Lima J.A.C., et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005, 352:539-548.
85. Sharkey S.W. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation 2005, 111:472-479.
86. Nef H.M., Mollmann H., Kostin S., et al. Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. Eur Heart J 2007, 28:2456-2464.
87. Elesber A.A., Prasad A., Lennon R.J., Wright R.S., Lerman A., Rihal C.S. Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol 2007, 50:448-452.
88. Eitel I., Knobelsdorff-Brenkenhoff von F., Bernhardt P., et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 2011, 306:277-286.
89. Rahko P.S., Salerni R., Uretsky B.F. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. JAC 1986, 8:436-440.
90. Rivers J., Garrahy P., Robinson W., Murphy A. Reversible cardiac dysfunction in hemochromatosis. Am Heart J 1987, 113:216-217.
91. Chow C.H., El-Amm C., Liu W., Pastva S., Sipahi I., Fang J.C. Reversal of severe biventricular dysfunction from cardiac hemochromatosis with iron removal. Circ Heart Fail 2013, 6:e14-e15.
92. Gujja P., Rosing D.R., Tripodi D.J., Shizukuda Y. Iron overload cardiomyopathy. JAC 2010, 56:1001-1012.